Cancer Center

A new multicenter study hopes to ascertain whether the adjuvant implementation of personalized cancer vaccine mRNA-4157, in combination with pembrolizumab, improves recurrence-free survival (RFS) when compared with pembrolizumab alone in patients who have had a complete resection of cutaneous melanoma and also have a high-risk of recurrence. The primary endpoint of this trial will be RFS.

Learn more by clicking here.